Moderna's early hantavirus vaccine research has boosted stock price, reflecting market interest. The vaccine is in initial ...
After news came out that Moderna has been secretly working on a Hantavirus vaccine, the MRNA share price rocketed +5% ...
Moderna reported positive Phase 3 results for its mRNA seasonal influenza vaccine candidate, mRNA-1010, showing stronger ...
This development renewed investor confidence in Moderna’s mRNA pipeline, even as a cluster of hantavirus cases emerged on a ...
Moderna shares rally as investors bet on recent Hantavirus outbreak accelerating the biotech firm’s path to profitability.
Moderna Inc MRNA shares are trading higher Friday morning as traders react to peer reviewed Phase 3 flu-vaccine data. Here’s ...
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...
A hantavirus vaccine is currently in preclinical development, but a publicly available shot is likely years away. Other ...
The world’s first combination seasonal influenza and COVID-19 vaccine, Moderna’s mCombriax, has received marketing ...
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, ...
The deadly hantavirus outbreak linked to the cruise ship MV Hondius has reignited global interest in vaccines against one of ...
By Julie Steenhuysen, Siddhi Mahatole and Mariam Sunny May 1 (Reuters) - Moderna surpassed Wall Street estimates for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results